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The p38 MAPK pathway regulates multiple neutrophil
functional responses via activation of the serine-threo-
nine kinase MAPK-activated protein kinase 2 (MAP-
KAPK2). To identify substrates of MAPKAPK2 that me-
diate these responses, a proteomic approach was used in
which in vitro phosphorylation of neutrophil lysates by
exogenously added active recombinant MAPKAPK2 was
followed by protein separation using two-dimensional
electrophoresis. Peptide mass fingerprinting of pep-
tides defined by MALDI-MS was then utilized to identify
phosphorylated proteins detected by autoradiography.
Six candidate substrates were identified, including the
p16 subunit of the seven-member Arp2/3 complex (p16-
Arc). In vitro studies confirmed that MAPKAPK2 inter-
acts with and phosphorylates the A isoform, but not the
B isoform, of p16-Arc with a stoichiometry of 0.6 to 0.7.
MAPKAPK2 also phosphorylated p16-Arc in intact
Arp2/3 complexes precipitated from neutrophil lysates.
Mutation of serine-77 to alanine on the A isoform pre-
vented phosphorylation by MAPKAPK2. The ability of
MAPKAPK2 to phosphorylate one isoform of p16-Arc
suggests a possible mechanism by which the p38
MAPK cascade regulates remodeling of the actin
cytoskeleton.
MAPK1 cascades are modules containing three kinases, in-
cluding a MAPK, which is activated by a dual specificity serine-
threonine/tyrosine kinase called MAPK/extracellular signal-
regulated kinase kinase (MEK), which in turn is activated by a
serine-threonine kinase termed MEK kinase (MEKK) (1, 2).
One of the cascades, p38 MAPK, is activated in human neutro-
phils by numerous pro-inflammatory stimuli, including che-
moattractants, chemokines, bacterial phagocytosis, Fc recep-
tor cross-linking, lipopolysaccharide, tumor necrosis factor-,
and granulocyte-macrophage colony-stimulating factor (3–10).
Activation of p38 MAPK is required for a number of neutrophil
functions, including chemotaxis, chemokine expression, respi-
ratory burst activity, exocytosis, and priming (8, 11–18). Stud-
ies using animal models confirm a role for p38 MAPK in in-
flammatory diseases (19–25).
The molecular pathways leading from p38 MAPK to various
functional responses in neutrophils have not been fully defined.
Of the possible targets for p38 MAPK phosphorylation, only the
serine-threonine kinase, MAPK-activated protein kinase 2
(MAPKAPK2), has been identified in neutrophils (26). Zu et al.
(27) report that a peptide inhibitor of MAPKAPK2 attenuated
neutrophil respiratory burst activity stimulated by formylme-
thionylleucylphenylalanine. Using the same peptide, we
showed MAPKAPK2 also participated in exocytosis and che-
motaxis (28). Hannigan et al. (26) recently reported that neu-
trophils from MAPKAPK2/ mice demonstrated impaired
directional migration, whereas adherence was normal. Thus,
MAPKAPK2 appears to be a critical downstream kinase for a
number of p38 MAPK-dependent neutrophil functions. Previ-
ously identified targets of MAPKAPK2 phosphorylation in neu-
trophils include two actin-binding proteins, heat shock protein
(Hsp) 27 and leukocyte-specific protein 1 (LSP1), Akt, and
5-lipooxygenase (29–32). The functional significance of MAP-
KAPK2 phosphorylation of Hsp27 and 5-lipooxygenase has not
been determined, whereas LSP1 participates in neutrophil che-
motaxis (33). To define the signal transduction pathways that
control p38 MAPK-mediated functional responses in neutro-
phils, a more complete list of MAPKAPK2 substrates is
required.
To identify MAPKAPK2 substrates, we developed a pro-
teomic approach using a combination of in vitro phosphoryla-
tion of neutrophil lysate by exogenous active recombinant
MAPKAPK2, protein separation by two-dimensional electro-
phoresis, and phosphoprotein identification by matrix-assisted
laser desorption and ionization-mass spectrometry (MALDI-
MS). Approximately 30 proteins were phosphorylated by MAP-
KAPK2, as determined by autoradiography of two-dimensional
gels. Initial studies identified six proteins as potential sub-
strates, including the known substrate LSP1. One of the pre-
viously unknown substrates identified was p16-Arc, a subunit
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of the Arp2/3 complex. The Arp2/3 complex regulates actin
polymerization and cross-linking, and this complex is neces-
sary for neutrophil chemotaxis and phagocytosis (34–36). Two
isoforms of p16-Arc have recently been described, both of which
are expressed in humans neutrophils (37). To confirm that
p16-Arc is a true substrate of MAPKAPK2, we characterized
the ability of MAPKAPK2 to interact with and phosphorylate
each of the two p16-Arc isoforms, p16-A and p16-B. Our results
indicate that MAPKAPK2 interacts with and phosphorylates
p16-A, whereas p16-B is relatively resistant to MAPKAPK2
phosphorylation.
EXPERIMENTAL PROCEDURES
Materials—The constructs for pGEX-5X-2-p16A and B as well as
pGEX-5X-2-WA and W (SCAR) were described previously (38). Expres-
sion of glutathione S-transferase (GST)-MAPKAPK2 fusion protein was
accomplished by constructing a pGEX-5X-2 (Amersham Biosciences)
expression plasmid with the human cDNA for MAPKAPK2 (obtained
from Dr. Matthias Gaestel, Martin Luther University, Halle-Witten-
berg, Germany) downstream of GST. Recombinant His-p16A and His-
p16B were expressed by cloning a BamHI/EcoRI insert from pGEX-5X-
2p16A and B into pRSETA (Invitrogen). [S35]Methionine-labeled p16-A
and p16-B were expressed with the TNT Quick Master expression kit
(Promega, Madison, WI).
Ser-77 on pRSET-p16A was mutated to alanine with Clontech trans-
former site-directed mutagenesis kit using 5-CCGGGCAGGCGCCAT-
TGTCTTG-3 as the mutation primer and 5-GGAATTCGAACCTT-
GATCCGG-3 as the selection primer. The appropriate mutation was
verified by DNA sequencing. His-tagged p16-A S77A was bacterially
expressed and isolated by nickel chromatography.
Neutrophil Isolation—Neutrophils were isolated from healthy donors
using plasma-Percoll gradients as described by Haslett et al. (39). After
isolation, neutrophils were suspended in Krebs-Ringer phosphate
buffer, pH 7.2, at the desired concentration. The study was approved by
the University of Louisville Human Studies Committee.
Neutrophil Lysate Preparation for MAPKAPK2 Substrate Identifica-
tion—Neutrophils (1  108) were lysed in 400 l of lysis buffer contain-
ing 2 M thiourea, 7 M urea, 65 mM CHAPS, 58 mM dithiothreitol, and
4.5% ampholytes (pI 3–10) (final pH  6.4). Lysates were centrifuged at
14,000 rpm for 20 min at 15 °C. Before the addition of exogenous
MAPKAPK2, urea concentration of lysates was reduced to 1 M by size
exclusion chromatography. One ml spin-out columns (Chemicon Inter-
national, Inc., Temecula, CA) were equilibrated in kinase buffer (25 mM
HEPES, 25 mM -glycerophosphate, 25 mM MgCl2, 2, mM dithiothreitol,
0.1 mM NaVO3, 65 mM CHAPS) containing 4 M or 1 M urea. Neutrophil
lysate (400 l) was loaded on the column equilibrated with the buffer
containing 4 M urea and centrifuged at 500  g for 1 min. The procedure
was repeated with buffer containing 1 M urea. The lysate was stored at
20 °C.
MAPKAPK2 Substrate Identification—Neutrophil lysates (400 g of
total protein) were incubated with 10 Ci of [-32P]ATP (ICN Biomedi-
cals, Inc.) in the presence and absence of 400 ng of active recombinant
MAPKAPK2 (Upstate Biotechnology, Lake Placid, NY) at 30 °C for 3 h.
Kinase reactions were stopped by adding rehydration buffer (8 M urea,
2% CHAPS, 0.01 M dithiothreitol, 2% ampholytes 3–10, and 0.01%
bromphenol blue) to give a total volume of 450 l. Proteins were sepa-
rated by isoelectric focusing with pH 3–10 immobilized pH gradient
(IPG) strips and by size with 10% DuracylTM (Genomic Solutions, Ann
Arbor, MI). IPG strips were rehydrated in buffer containing 400 g of
protein and focused isoelectrically at 5000 Vmax and 80 mA/gel for
100,000 V-h. After isoelectric focusing, IPG strips were sequentially
incubated for 10 min in equilibration buffers I (6 M urea, 2% dithiothre-
itol, 30% glycerol) and II (6 M urea, 2.5% iodoacetamide, 30% glycerol).
IPG strips were then applied to 10% Duracryl gels, and proteins were
separated using a Tricine buffer system (upper reservoir buffer: 0.1 M
Tricine, 0.1 M Tris, 0.1% SDS, pH 8.5; lower buffer: 0.2 M Tris-acetate,
pH 8.9) at 500 V for 4–5 h. Gels were silver-stained, and phosphoryla-
tion was visualized by autoradiography.
Trypsin Digestion and Mass Spectrometry Analysis—To obtain pep-
tides for mass spectrometry analysis, protein spots were excised and
digested with trypsin by modification of the method of Jensen et al. (40).
The excised gel pieces were incubated for 15 min in 100 mM NH4HCO3
and 50% acetonitrile and dried by vacuum centrifugation. Proteins were
then reduced by incubation with 20 mM dithiothreitol at 56 °C for 45
min followed by alkylation with 65 mM iodoacetamide in the dark at
room temperature for 30 min. Post-alkylation gel pieces were incubated
for 15 min in 100 mM NH4HCO3 and 50% acetonitrile and dried by
vacuum centrifugation, and then proteins were hydrolyzed by incuba-
tion in 20 ng/ml modified trypsin (Promega) at 37 °C overnight. Tryp-
sin-generated peptides were applied by a thin film-spotting procedure
for MALDI-MS analysis using -cyanohydroxycinnamic acid as the
matrix on stainless steel targets, as described by Jensen et al. (40).
Mass spectral data were obtained using a Tof-Spec 2E (Micromass) and
a 337-nm N2 laser at 20–35% power in the reflector mode. Spectral data
were obtained by averaging 10 spectra, each of which was the composite
of 10 laser firings. Mass axis calibrations were accomplished using
peaks from tryptic auto-hydrolysis. Peptide masses obtained by
MALDI-MS analysis were used to search the National Center for Bio-
technology Information data base (NCBI, www.matrixscience.com) to
identify the intact proteins. A MOWSE score 71 indicated a signifi-
cant match, ensuring the probability of the match not being a random
event.
In Vitro Kinase Assays—Phosphorylation of recombinant p16-A and
p16-B by MAPKAPK2 was examined by incubation of active recombi-
nant MAPKAPK2 (40 ng) with 10 Ci of [-32P]ATP and 0.5 g of
recombinant protein in 30 l of kinase buffer containing 25 mM HEPES,
25 mM -glycerophosphate, 25 mM MgCl2, 2 mM dithiothreitol, and 0.1
mM NaVO3, pH 7.2. Reactions were incubated at 30 °C for 1 h. After the
incubation, reactions were terminated with Laemmli SDS sample dilu-
tion buffer, proteins were separated by 15% SDS-PAGE, and phospho-
rylation was visualized by autoradiography.
To determine the time course of Hsp27 and p16-A phosphorylation,
400 ng of recombinant active MAPKAPK2 were incubated with 0.5 g
of recombinant Hsp27 or p16-A and 10 Ci of [-32P]ATP at 30 °C for
times ranging from 30 min to 4 h. Optimal phosphorylation of both
substrates was seen between 2 and 3 h. To determine the stoichiometry
of phosphorylation, 400 ng of recombinant active MAPKAPK2 were
incubated with 0.05, 0.1, and 0.3 g of Hsp27 or 0.5, 1, and 2 g of
p16-A, 2 pmol of [-32P]ATP, and 200 pmol of ATP in 200 l of kinase
buffer at 30 °C for 3 h. To separate free ATP from radiolabeled proteins,
the reaction mixture was applied to a prewashed Spin-out 6000 Micro
column (Chemicon International, Inc.) and collected into 200 l of
kinase buffer. Separate reaction mixtures containing 200 pmol of ATP
and 2 pmol of [-32P]ATP in 200 l of kinase buffer were used to
determine the specific activity of ATP in each reaction. Fifty l of each
sample was counted by scintillation spectrometry, and the molar ratio
of phosphorylation was calculated.
GST Pull Down—Neutrophil lysates were prepared by suspending
5  107 cells in 200 l of lysis buffer containing 20 mM Tris, pH 7.4, 1%
Triton X-100, 0.5% Nonidet P-40, 150 mM NaCl, 25 mM MgCl2, 20 mM
NaF, 0.2 mM NaVO3, 1 mM EDTA, 1 mM EGTA, 5 mM phenylmethyl-
sulfonyl fluoride, and 10% glycerol. GST, GST-p16A, or GST-p16B
glutathione-coupled Sepharose were incubated with neutrophil ly-
sate (400 g of protein) overnight at 4 °C. After incubation, beads
were washed 4 times with lysis buffer. Proteins were eluted with 6
Laemmli SDS sample dilution buffer, separated by 10% SDS-PAGE,
and immunoblotted for MAPKAPK2 using a polyclonal anti-
MAPKAPK2 antibody (Sigma).
GST pull downs of recombinant proteins were carried out by incu-
bating GST or GST-MAPKAPK2 glutathione-coupled Sepharose with
recombinant 35S-labeled p16-A or 35S-labeled p16-B in 50 l of kinase
buffer containing 25 mM HEPES, 25 mM -glycerophosphate, 25 mM
MgCl2, 2 mM dithiothreitol, 0.1 mM NaVO3, and 10% glycerol for 2 h at
4 °C. Beads were then washed 4 times with kinase buffer, proteins were
eluted with Laemmli SDS sample dilution buffer and separated by 15%
SDS-PAGE, and the [S35]methionine-labeled proteins were detected by
autoradiography.
In separate experiments, the Arp2/3 complex was precipitated
from neutrophil extract as previously described (38). Briefly, lysate
was subjected to pull-down by GST or GST fused to the C-terminal
region (WA) of the Scar1 protein that interacts with the Arp2/3
complex. GST fused to a truncated portion of the WA protein, termed
GST-W, was utilized as a negative control. One aliquot of each pre-
cipitate was eluted with Laemmli buffer and separated by 12% SDS-
PAGE, transferred to nitrocellulose membrane, and subsequently
immunoblotted for Arp3 using a polyclonal anti-Arp3 antibody (Santa
Cruz, CA). A second aliquot was suspended in kinase buffer (25 mM
HEPES, 25 mM -glycerophosphate, 25 mM MgCl2, 2 mM dithiothre-
itol, and 0.1 mM NaVO3) in the presence and absence of 40 ng of active
recombinant MAPKAPK2 and [-32P]ATP. Reactions were incubated
at 30 °C for 1 h. After incubation, reactions were terminated by the
addition of Laemmli SDS sample dilution buffer, proteins were sep-
arated by 15% SDS-PAGE, and phosphorylation was visualized by
autoradiography.
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Structural Modeling—The starting models were based on the p16-
Arc protein in the Arp2/3 x-ray crystal structure (41). The A isoform of
p16-Arc was generated by homology modeling with p16-Arc in the
crystal structure using Modeler (42) and an alignment generated with
ClustalW (43). The S77A-mutated p16-Arc was created by replacing the
Ser-77 with Ala in a standard conformation. The simulations to deter-
mine the effect of the S77A mutation on p16-Arc core structure included
the central core of p16-Arc (residues 35–151) but did not include the
first 34 residues that interact with Arp2 and p41-Arc, as this region of
p16-Arc is dynamic, and the structure is stabilized by interaction part-
ners that were not included in the calculations.
Models were hydrated in a 10 box of TIP3P waters using standard
AMBER (44) (amber.scripps.edu) rules; Cl counterions were placed
randomly for charge neutrality. Box sizes were adjusted to include 7060
waters for each model. Simulations were performed in the isothermal
isobaric ensemble (300 K, 1 atm) with the AMBER 7.0 program (43) and
parameters from parm96.dat using periodic boundary conditions and
the PME algorithm. Molecular dynamics simulations used the message
passing interface version of the Sander routine (1.5-fs time step) with
SHAKE to freeze all bonds involving hydrogen. Initial equilibrium for
155 ps following the general protocol (44) were performed with gradual
removal of positional restraints on the protein complex. The production
runs were 4.0 ns in length, and average structures for each complex
(taken from 50 snapshots accumulated in the last 50 ps) were obtained
and subsequently minimized. The calculations were run on a 32 proc-
essor SGI Origin 2000.
RESULTS
Identification of MAPKAPK2 Substrates—MAPKAPK2 sub-
strate screening was performed by incubating human neutro-
phil lysates with [-32P]ATP in the presence and absence of
active recombinant MAPKAPK2. Proteins were separated by
two-dimensional gel electrophoresis, gels were stained, and
phosphorylated proteins were visualized by autoradiography.
Autoradiographs were compared with silver-stained gels to
identify the proteins that were MAPKAPK2 substrates (Fig. 1).
No phosphorylation was observed after incubation of neutro-
phil lysates with [-32P]ATP in the absence of active recombi-
nant MAPKAPK2, indicating the absence of endogenous kinase
activity under the conditions of neutrophil lysate preparation.
In the presence of active recombinant MAPKAPK2 more than
30 proteins demonstrated phosphorylation. Six proteins iden-
tified as candidate MAPKAPK2 substrates by this method are
marked on the autoradiograph in Fig. 1. LSP1 and myosin
regulatory light chain were previously shown to be substrates
for MAPKAPK2 (30, 46). A phosphorylated protein with a mo-
lecular mass below 25 kDa was identified as p16-Arc with 56%
protein coverage (Table I). The possibility that p16-Arc was a
false positive was considered for several reasons. First, cell
lysis may permit access of exogenous kinases to proteins with
restricted localization in intact cells. Second, urea denaturation
may expose phosphorylation sites that are inaccessible in prop-
erly folded proteins. Third, disruption of protein-protein inter-
actions may result in dissociation of signaling modules that
direct kinase activity. Finally, protein spots may contain more
than one protein, leading to identification of false substrates.
Therefore, additional studies were performed to confirm the
ability of MAPKAPK2 to interact with and phosphorylate
p16-Arc.
MAPKAPK2 Interacts With and Phosphorylates p16-Arc—
p16-Arc was recently shown to consist of two different isoforms,
p16-A and p16-B, which are differentially expressed in various
tissues and may determine which proteins bind to the intact
Arp2/3 complex (40). To determine whether MAPKAPK2 inter-
acts with p16-A and p16-B, GST-MAPKAPK2 pull-down of
recombinant 35S-labeled p16-Arc isoforms was performed by
incubating GST or GST-MAPKAPK2 glutathione-coupled
Sepharose with recombinant [35S]p16-A or [S35]p16-B. Fig. 2A
shows that GST-MAPKAPK2 coupled, but not GST-coupled,
glutathione-Sepharose precipitated p16-A. Neither GST-MAP-
KAPK2 nor GST-glutathione-Sepharose was able to precipitate
p16-B (Fig. 2B). To determine whether endogenous MAP-
KAPK2 in neutrophil lysates interacts with p16-A or p16-B,
neutrophil lysates were incubated with recombinant GST,
GST-p16-A, or GST-p16-B coupled to glutathione-Sepharose.
Precipitated proteins were separated by SDS-PAGE followed
by immunoblotting for MAPKAPK2. Figs. 3, A and B, show that
endogenous MAPKAPK2 was precipitated by GST-p16-A but
not by GST-p16-B or GST-glutathione-Sepharose. These data
suggest that MAPKAPK2 physically associates with p16-A but
not p16-B.
To determine whether the interactions with MAPKAPK2
result in p16-Arc phosphorylation, active recombinant MAP-
KAPK2 was incubated with equivalent amounts of recombi-
nant p16-A or p16-B and [-32P]ATP in an in vitro kinase
assay. The proteins were separated by 15% SDS-PAGE and
subjected to autoradiography. Fig. 4A shows that, despite equal
loading of p16-A and p16-B, MAPKAPK2-phosphorylated
p16-A more extensively than p16-B. A search of the amino
acid sequences of p16-A and p16-B determined that p16-A
contains a motif similar to the consensus MAPKAPK2 phos-
phorylation motif (KDRAGS77) that is absent in the B iso-
form. To determine whether this consensus site was the
primary phosphorylation site, serine 77 was mutated to
alanine (p16-A S77A). Fig. 4B shows that substitution of
alanine for Ser-77 completely inhibited MAPKAPK2 phos-
phorylation of p16-A. These data suggest that MAPKAPK2
directly interacts with and phosphorylates the A isoform
of p16-Arc at Ser-77, whereas interaction with and phos-
phorylation of the B isoform is minimal.
The time course of Hsp27 and p16-A phosphorylation by
MAPKAPK2 were similar under identical incubation condi-
tions. At 30 °C maximal phosphorylation occurred between 2
FIG. 1. Phosphorylation of neutrophil lysate by recombinant
active MAPKAPK2. Candidate MAPKAPK2 substrates were identi-
fied by phosphorylation of neutrophil lysates with [-32P]ATP in the
presence and absence of active recombinant MAPKAPK2. Proteins were
separated by two-dimensional gel electrophoresis and phosphoproteins
detected by autoradiography. Proteins were identified by comparing
autoradiographs (panels A and C) with their corresponding silver-
stained gels (panels B and D). No endogenous kinase activity was
detected in neutrophil lysates incubated without active recombinant
MAPKAPK2 (panel C). Six candidate substrates of MAPKAPK2 were
identified by peptide mass fingerprinting of trypsin-digested phospho-
proteins using MALDI-MS and protein data base analysis (numbered
arrows). These proteins were LSP1 (1), integrin-linked kinase (2), pro-
teosome activator 1 (3), myosin regulatory light chain (4), cyclophilin A
(5), and p16-Arc (6).
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and 3 h for both proteins (Fig. 4C). Stoichiometry of phospho-
rylation was 0.6 and 0.7 mol of phosphate/mol of protein for
p16-A in two separate experiments. The stoichiometry of phos-
phorylation for Hsp27 was calculated at 4 mol of phosphate/mol
of Hsp27. Previous studies identified up to 4 sites of phospho-
rylation on Hsp27, Ser-15, Ser-78, Ser-82, and Ser-90 (47–49).
Phosphorylation of p16-Arc in the Arp2/3 Complex—To de-
termine whether MAPKAPK2 phosphorylated p16-Arc in the
intact Arp2/3 complex, we precipitated the entire complex from
the neutrophil lysate. The Scar-1 protein directly binds to and
activates the Arp2/3 complex (34, 50). The C-terminal region of
Scar-1, termed Scar-WA, is responsible for this interaction, and
GST-Scar-WA precipitates the intact Arp2/3 complex from cell
lysates (38). A truncated form of the WA protein, termed
Scar-W, fails to bind to Arp2/3 complex and was used as a
negative control. Neutrophil lysates were incubated with GST,
GST-WA, or GST-W coupled to glutathione-Sepharose. Ali-
quots of each assay were used to confirm the precipitation of
the Arp2/3 complex by immunoblotting for Arp3. Fig. 5A shows
that GST-WA, but not GST-W or GST, precipitated the Arp2/3
complex from lysates. An in vitro kinase assay was performed
by the addition of active recombinant MAPKAPK2 to an aliquot
of each precipitate. Fig. 5B demonstrates that MAPKAPK2
phosphorylated a 16-kDa protein precipitated by GST-WA but
not GST-W or GST alone. These data suggest that MAPKAPK2
phosphorylates p16-Arc when it is a component of the intact
Arp2/3 complex.
The p16-Arc subunit is bound to Arp2 and p41-Arc at the
base of the Arp2/3 complex (Fig. 6A). The Ser-77 residue of
p16-Arc identified as the MAPKAPK2 phosphorylation site is
located on the fifth  helix, as defined by the crystal structure,
FIG. 2. MAPKAPK2 interacts with p16-Arc isoforms. To deter-
mine whether MAPKAPK2 interacts with p16-A and p16-B, recombi-
nant [35S]methionine-labeled p16-A (panel A) or p16-B (panel B) was
incubated with GST (first lane, panels A and B) or GST-MAPKAPK2
glutathione coupled Sepharose (second lane, panels A and B) and sub-
jected to a pull-down assay. Proteins associated with the Sepharose
beads were separated by SDS-PAGE and visualized by autoradiogra-
phy. p16-A, but not p16-B, precipitated with MAPKAPK2. The third
lane in both panels represents radiolabeled recombinant proteins run
as a positive control.
FIG. 3. Interaction of p16-Arc isoforms with MAPKAPK2 in
neutrophil lysate. To determine whether endogenous MAPKAPK2
interacts with p16-A and p16-B, neutrophil lysates (400 g of protein)
were incubated with GST-p16-A (panel A, first lane) or GST-p16-B
(panel B, fourth lane) and subjected to a pull-down assay. GST
glutathione-Sepharose (first lane, panels A and B), GST-p16-A
coupled to glutathione-Sepharose (third lane, panel A), GST-p16-B
coupled to glutathione-Sepharose (third lane, panel B), and neutro-
phil lysate (fifth lane, panels A and B) were used as controls. Proteins
were separated by SDS-PAGE and immunoblotted (IB) for
MAPKAPK2. Immunoblots show that MAPKAPK2 precipitated with
p16-A but not with p16-B.
TABLE I
Identification of p16-Arc as an MAPKAPK2 substrate
Peptide mass fingerprint analysis of a 16-kDa neutrophil protein phosphorylated by active recombinant MAPKAPK2 (Fig. 1) matches seven
peptide masses with p16-Arc. The total coverage is 56% of the protein. Peptides covered in p16-Arc are shown in bold letters.
Masses submitted Masses matched Start End Peptide
705.44 706.35 82 87 VLISFK
1069.62 1070.71 132 143 ALAAGGVGSIVR
1315.69 1316.71 48 60 QGNMTAALQAALK
1352.61 1353.64 13 23 KVDVDEYDENK
2161.97 2162.99 113 131 GFESPSDNSSAMLLQWHEK
2552.04 2553.05 24 47 FVDEEDGGDGQAGPDEGEVDSCLR
3758.54 3759.24 14 47 VDVDEYDENKFVDEEDGGDGQAGPDEGEVDSCLR
1 MSKNTVSSAR FRKVDVDEYD ENKFVDEEDG GDGQUAGPDEG EVDSCLRQGN
51 MTAALQAALK NPPINTKSQA VKDRAGSIVL KVLISFKAND IEKAVQSDLDK
121 NGVDLLMKYI YKGFESPSDNSSAMLLQWHE KALAAGGVGS IVRVLTARKT
151 V
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situated between helices 8 and 9 (orthogonal to helix 5) and
helices 3 and 4 (parallel to helix 5). The Ser-77 residue is
located in the center of helix 5, and the side chain is exposed
with no structural interaction with other p16-Arc residues (Fig.
6B). Thus, it is accessible for interaction with and phosphoryl-
ation by MAPKAPK2. The identification of Ser-77 as the site of
phosphorylation by MAPKAPK2 depends on the absence of
significant structural alterations in p16-A S77A. Therefore, the
structural alterations produced by this mutation were pre-
dicted by computer-generated structural modeling. Fig. 6C de-
picts the results of this modeling, which predicted no major
local structural perturbations caused by the S77A mutation.
Additionally, the mutation site is remote to the binding sites of
p16-Arc to Arp2 and p41-Arc. These results suggest that the
S77A mutation does not produce structural changes that would
interfere with MAPKAPK2 phosphorylation of amino acid res-
idues distinct from Ser-77.
MAPKAPK2 Interacts with the Arp2/3 Complex in Neutro-
phils—To determine whether MAPKAPK2 interacts with the
Arp2/3 complex in human neutrophils, this complex was pre-
cipitated from neutrophil lysates, and MAPKAPK2 was de-
tected by immunoblot analysis. GST-WA coupled to glutathi-
one-Sepharose was used to precipitate the Arp2/3 complex,
whereas GST and GST-W coupled to glutathione-Sepharose
were used as controls. Fig. 7A demonstrates that MAPKAPK2
was present in the complex precipitated by GST-WA but not
GST-W or GST. To confirm that the Arp2/3 complex was only
precipitated by GST-WA, the blots were stripped and reprobed
for Arp3 (Fig. 7B). These data indicate that MAPKAPK2 inter-
acts with the Arp2/3 complex in intact neutrophils.
DISCUSSION
Transient phosphorylation of serine, threonine, or tyrosine is
a common mechanism of signal transduction. Phosphorylation
can alter the catalytic activity or conformation of a protein or
create binding sites for protein-protein interactions. A variety
of approaches have been developed to identify proteins that
interact with or are phosphorylated by kinases. The limitations
associated by each approach prevent any one method from
being universally applicable. For example, whereas the tran-
scriptional-based yeast two-hybrid system is an extremely sen-
sitive method to study protein-protein interactions, proteins
must be expressed in the nucleus and cannot possess transcrip-
tional activity. Approaches utilizing [32P]ATP labeling of ki-
FIG. 4. In vitro MAPKAPK2 phosphorylation of p16-Arc iso-
forms. Panel A, equal amounts of recombinant p16-A (second lane) and
p16-B (first lane) were subjected to an in vitro kinase assay with
[-32P]ATP and active recombinant MAPKAPK2. Proteins were sepa-
rated by 15% SDS-PAGE, and results were visualized by autoradiogra-
phy. Autoradiographs show that p16-A was extensively phosphorylated
compared with p16-B. Phosphorylation of recombinant Hsp27 by MAP-
KAPK2 was used as the control (third lane). Panel B, recombinant
active MAPKAPK2 was incubated with [-32P]ATP and recombinant
p16-A wild type (WT) (second lane) or p16-A S77A (first lane). Proteins
were separated by SDS-PAGE, and results were visualized by autora-
diography. Autoradiographs show that MAPKAPK2 phosphorylated
p16-A WT, but not p16-A (S77A). The third lane represents MAP-
KAPK2-phosphorylated recombinant Hsp27 run as a positive control.
Panel C, the time course of phosphorylation of p16-A and Hsp27 by
MAPKAPK2 is shown. Hsp27 (2 g) or p16-A (1 g) were incubated
with 400 ng of recombinant active MAPKAPK2 in the presence of
[-32P]ATP at 30 °C for 30 min to 4 h. Optimal phosphorylation was
visualized between 2 and 3 h for both proteins.
FIG. 5. GST pull-down of Arp2/3 complex from neutrophil ly-
sate. Panel A, neutrophil lysate was incubated with GST-coupled to
glutathione-Sepharose (first lane), coupled to GST-WA (second lane), or
GST-W (third lane). Proteins were separated by SDS-PAGE and immu-
noblotted for Arp3. Immunoblots (IB) confirm that GST-WA, but not
GST-W or GST, precipitated the Arp2/3 complex from neutrophil lysate.
The fourth lane represents neutrophil lysate run as a positive control.
Panel B, neutrophil lysate was incubated with GST coupled to gluta-
thione-Sepharose (first lane), GST-WA-coupled glutathione-Sepharose
(second lane), or GST-W-coupled glutathione-Sepharose (third lane).
Aliquots from the pull-down assay were incubated with active recom-
binant MAPKAPK2 in presence of [-32P]ATP. Proteins were separated
by 10% SDS-PAGE, and results were visualized by autoradiography.
Autoradiographs show that MAPKAPK2 phosphorylated a 16-kDa pro-
tein only in the assay containing the intact Arp2/3 complex. Phospho-
rylation of recombinant p16-A by MAPKAPK2 was used as a positive
control (fourth lane).
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nase substrates in intact cells have proven effective; however,
identification of specific substrates is complicated by activation
of multiple kinases under basal conditions and after physiolog-
ical stimuli. Genetic introduction of constitutively active and
dominant negative kinases reduces interference from endoge-
nous kinases, but this approach requires long-lived isolated
cells, usually in the form of transformed cell lines. Additionally,
the ability to simultaneously identify a large number of protein
substrates has until recently been limited by available
technology.
We report here a proteomic approach that allows the identi-
fication of multiple substrates of a single kinase. This approach
involves the in vitro phosphorylation of cellular lysate by re-
combinant kinase followed by two-dimensional gel electro-
phoresis. The phosphoproteins are subsequently identified by
MALDI-MS. This methodology eliminates the need for phar-
macological kinase inhibitors or the genetic introduction of
mutant kinases into intact cells. The use of urea based lysis
buffer improves protein solubility, effectively separates pro-
teins from interfering lipids, salts, and nucleic acids, and elim-
inates endogenous kinase activity. Additionally, urea dena-
tures and inactivates proteases that degrade cellular proteins.
The preparatory methods described herein may also be appli-
cable to methods for phosphopeptide enrichment by metal che-
lation columns, chemical modification for affinity chromatog-
raphy, and tandem mass spectrometry.
The proteomic approach described, however, also possesses a
number of limitations. For some phosphorylated proteins, in-
sufficient mass spectra for identification were observed. Possi-
ble explanations included phosphorylation of low abundance
proteins, incomplete trypsin digestion, interference of the sil-
ver stain with extraction of peptides from the gel, or incomplete
protein transfer from the IPG strips to the second dimension
gel. Because of the problems created by silver staining, we are
now using a fluorescent-based dye (Sypro Ruby®), which has a
greater dynamic range for protein expression and does not
impair extraction of peptides from the gel (51). False positives
may be generated for several reasons. Cell lysis may permit
access of an exogenously added kinase to proteins with re-
stricted localization in intact cells. Urea denaturation may
expose phosphorylation sites that are inaccessible in properly
folded proteins. Disruption of protein-protein interactions re-
sults in dissociation of signaling modules that direct kinase
activity. Finally, protein spots may contain more than one
protein, leading to identification of false substrates. On the
other hand, some substrates may be missed due to protein
unfolding leading to disruption of docking sites.
FIG. 6. Structure of the Arp2/3 com-
plex. Panel A depicts the structure of the
intact Arp2/3 complex as ribbons based on
the x-ray crystal structure, as described
under “Experimental Procedures.” p16-
Arc is shown in red, and Ser-77 is in green
as a Corey-Pauling-Koltun representa-
tion. Panel B is a magnification of the box
in panel A showing p16-Arc (red) and the
Corey-Pauling-Koltun representation of
Ser-77 (green) in the fifth  helix. The
figure demonstrates that side chain of
Ser-77 is exposed, potentially allowing ac-
cess to kinases. Panel C compares the rib-
bon representation of wild type p16-Arc
(red) with that of p16-A S77A (white).
This figure demonstrates that substitu-
tion of Ala for Ser-77 does cause signifi-
cant alterations in secondary structure.
FIG. 7. MAPKAPK2 interacts with the Arp2/3 complex in neu-
trophils. Panel A, the Arp2/3 complex was precipitated from neutrophil
lysates by incubating with GST-coupled glutathione-Sepharose, GST-
W-coupled glutathione-Sepharose, or GST-WA-coupled glutathione-
Sepharose. Proteins were separated by SDS-PAGE and immunoblotted
for MAPKAPK2. Immunoblots confirm that MAPKAPK2 co-precipi-
tated with GST-WA but not GST-W or GST. Neutrophil lysate served as
a positive control. Panel B, nitrocellulose membrane from the MAP-
KAPK2 immunoblot was stripped and reprobed with Arp3. The immu-
noblot confirms that GST-WA, but not GST-W or GST, precipitate the
Arp2/3 complex.
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From the 30 phosphorylation events observed by autora-
diography, we identified six potential MAPKAPK2 substrates;
LSP1, integrin-linked kinase, proteasome activator-1, myosin
regulatory light chain, cyclophilin-A, and p16-Arc. The identi-
fication of LSP1 and myosin regulatory light chain, both
previously identified as MAPKAPK2 substrates (30, 46), sup-
ports our proteomic approach. Because of the possibility of
false positive substrate identification, however, we consider
this approach to be a screening method requiring further
confirmation.
It has been postulated that the Arp2/3 complex acts as the
final common pathway for a variety of signaling inputs leading
to actin polymerization (38). The actin cytoskeleton is a dy-
namic filament network involved in multiple functions, includ-
ing cell locomotion, chemotaxis, phagocytosis, and vesicle exo-
cytosis. The Arp2/3 complex enhances actin nucleation and
causes branching and cross-linking in vitro. In intact cells the
Arp2/3 complex controls actin-based motility by driving the
formation of lamellipodia (34, 52–55). It has been shown that
neutrophils from MAPKAPK2-deficient mice have impaired
directional migration (26), and MAPKAPK2 is involved in res-
piratory burst activity, exocytosis, and chemotaxis (27, 28). Our
results indicate that MAPKAPK2 co-precipitated with the
Arp2/3 complex and MAPKAPK2 phosphorylated p16-Arc in
the intact Arp2/3 complex. The intensity of interaction and
phosphorylation differed significantly between the two p16-Arc
isoforms. The interaction of MAPKAPK2 with p16-A was clear-
cut, whereas the physical interaction with p16-B was negligi-
ble. Additionally, p16-A was phosphorylated by active recom-
binant MAPKAPK2 to a much greater extent than p16-B. By
mutational analysis, serine 77 was identified as the phospho-
rylation site on the p16-A isoform. This residue is contained in
a consensus MAPKAPK2 phosphorylation domain (KDRAGS)
(56), which is not present in the p16-B isoform. Our structural
analysis found that the Ser-77 residue is located in the center
of the fifth  helix of p16-A, and the side chain is exposed,
potentially allowing interaction with kinases. Additionally, the
secondary structure of p16-Arc was not significantly altered in
the S77A mutant. Thus, the failure of p16-A S77A to undergo
phosphorylation is unlikely to be due to an altered structure of
the mutant protein. Additionally, this MAPKAPK2 phospho-
rylation site is exposed when p16-A is contained in intact
Arp2/3 complexes. No MAPKAPK2 consensus sequence was
located on p16-B, and the site(s) of the minimal MAPKAPK2
phosphorylation is unknown.
The functional consequences of p16-Arc phosphorylation by
MAPKAPK2 and the role of differences in phosphorylation
between p16-A and p16-B remain to be determined. We spec-
ulate that MAPKAPK2 plays a regulatory role in Arp2/3 func-
tions only in cells expressing greater quantities of p16-A than
p16-B. The ability of MAPKAPK2 to phosphorylate p16-Arc in
the Arp2/3 complex from neutrophils and the preponderance of
p16-A in hematopoietic cells (37) supports the hypothesis that
MAPKAPK2 regulates Arp2/3 functions in human neutrophils
through phosphorylation of p16-Arc. MAPKAPK2 has been
recently implicated in hypoxia-related actin cytoskeleton
changes in endothelial cells via phosphorylation of its down-
stream substrate Hsp27 (57). Phosphorylation of p16-Arc by
MAPKAPK2 may provide an additional mechanism by which
the p38 MAPK cascade regulates cellular functions dependent
on the actin cytoskeleton.
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